Literature DB >> 23054488

The impact of persistent visually disabling vitreous floaters on health status utility values.

Haidong Zou1, Haiyun Liu, Xun Xu, Xi Zhang.   

Abstract

PURPOSE: To assess the time trade-off (TTO) utility values in patients with persistent visually disabling vitreous floaters (DVF) and to determine the reliability and validity of TTO methods in DVF patients.
METHODS: Prospective cross-sectional questionnaire survey: Eligible patients with persistent DVF referred to the Shanghai First People's Hospital outpatient service between January 2006 and February 2010, and randomly selected normal vision general population residents, were enrolled. All participants underwent TTO utility value evaluation. After 4-5 weeks, the patients were asked to undergo second TTO utility value evaluation during the follow-up interview.
RESULTS: The mean initial utility values of the 107 persistent DVF patients were 0.904 ± 0.054. Regression analyses revealed that length of education, visual acuity in the poorer-vision eye and employment status were associated with utility values (all P < 0.01). All patients took part in the follow-up interview; the intra-class correlation coefficient for TTO utility values at the initial and follow-up interviews was 0.855. In the 91 general population residents, the mean utility value was 0.923 ± 0.032, which was statistically higher than that of active study patients (t = 3.01, P < 0.01).
CONCLUSIONS: Persistent DVF can substantially diminish the patients' perception of their life, and can be measured by TTO utility values with high reliability and construct validity.

Entities:  

Mesh:

Year:  2012        PMID: 23054488     DOI: 10.1007/s11136-012-0256-x

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  25 in total

1.  Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration.

Authors:  Melissa M Brown; Gary C Brown; Sanjay Sharma; Jennifer Landy; Jeff Bakal
Journal:  Arch Ophthalmol       Date:  2002-04

2.  Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients.

Authors:  S Sharma; G C Brown; M M Brown; H Hollands; R Robins; G K Shah
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

3.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

Authors:  M M Brown; G C Brown; S Sharma; A F Smith; J Landy
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

4.  [Vitrectomy for floaters].

Authors:  J-C Quintyn; G Brasseur
Journal:  J Fr Ophtalmol       Date:  2004-05       Impact factor: 0.818

5.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

6.  Floaters and the quality of life.

Authors:  Jerry Sebag
Journal:  Am J Ophthalmol       Date:  2011-07       Impact factor: 5.258

7.  Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters.

Authors:  Y M Delaney; A Oyinloye; L Benjamin
Journal:  Eye (Lond)       Date:  2002-01       Impact factor: 3.775

8.  [Pars plana vitrectomy for idiopathic vitreous floaters].

Authors:  M Roth; P Trittibach; F Koerner; G Sarra
Journal:  Klin Monbl Augenheilkd       Date:  2005-09       Impact factor: 0.700

9.  Pars plana vitrectomy for persistent, visually significant vitreous opacities.

Authors:  W M Schiff; S Chang; N Mandava; G R Barile
Journal:  Retina       Date:  2000       Impact factor: 4.256

Review 10.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

View more
  9 in total

1.  Time Trade-off Utility Values in Noninfectious Uveitis.

Authors:  Katherine M Niemeyer; John A Gonzales; Thuy Doan; Erica N Browne; Maya M Rao; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2019-06-13       Impact factor: 5.258

2.  Endophthalmitis following 27-Gauge Pars Plana Vitrectomy for Vitreous Floaters.

Authors:  Zhong Lin; Rong Han Wu; Nived Moonasar
Journal:  Case Rep Ophthalmol       Date:  2016-11-25

3.  Surgical Outcomes of 27-Gauge Pars PLana Vitrectomy for Symptomatic Vitreous Floaters.

Authors:  Zhong Lin; Rui Zhang; Qi Hua Liang; Ke Lin; Yu Shu Xiao; Nived Moonasar; Rong Han Wu
Journal:  J Ophthalmol       Date:  2017-11-29       Impact factor: 1.909

4.  27-Gauge Vitrectomy for Symptomatic Vitreous Floaters with Topical Anesthesia.

Authors:  Zhong Lin; Nived Moonasar; Rong Han Wu; Robin R Seemongal-Dass
Journal:  Case Rep Ophthalmol       Date:  2017-01-20

5.  A comparison between topical and retrobulbar anesthesia in 27-gauge vitrectomy for vitreous floaters: a randomized controlled trial.

Authors:  Rong Han Wu; Rui Zhang; Zhong Lin; Qi Hua Liang; Nived Moonasar
Journal:  BMC Ophthalmol       Date:  2018-07-07       Impact factor: 2.209

6.  The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD.

Authors:  Tiezhu Lin; Tongtong Li; Xinmei Zhang; Yannian Hui; Salissou Moutari; Emmanuel Eric Pazo; Guangzheng Dai; Lijun Shen
Journal:  Ophthalmol Ther       Date:  2021-11-15

7.  Optical Scattering from Vitreous Floaters.

Authors:  Stuart W Harmer; Andrew J Luff; Giampaolo Gini
Journal:  Bioelectromagnetics       Date:  2021-12-30       Impact factor: 1.848

8.  Psychological Distress in Patients with Symptomatic Vitreous Floaters.

Authors:  Yong-Kyu Kim; Su Young Moon; Kyung Mi Yim; Su Jeong Seong; Jae Yeon Hwang; Sung Pyo Park
Journal:  J Ophthalmol       Date:  2017-12-10       Impact factor: 1.909

Review 9.  Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview.

Authors:  Andreas Katsanos; Nikoleta Tsaldari; Konstantina Gorgoli; Fotios Lalos; Maria Stefaniotou; Ioannis Asproudis
Journal:  Adv Ther       Date:  2020-02-21       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.